Literature DB >> 20078425

The Ig-like domain of human GM-CSF receptor alpha plays a critical role in cytokine binding and receptor activation.

Shamaruh Mirza1, Andrew Walker, Jinglong Chen, James M Murphy, Ian G Young.   

Abstract

GM-CSF (granulocyte/macrophage colony-stimulating factor) is an important mediator of inducible haemopoiesis and inflammation, and has a critical role in the function of alveolar macrophages. Its clinical applications include the mobilization of haemopoietic progenitors, and a role as an immune stimulant and vaccine adjuvant in cancer patients. GM-CSF signals via a specific alpha receptor (GM-CSFRalpha) and the shared hbetac (human common beta-subunit). The present study has investigated the role of the Ig-like domain of GM-CSFRalpha in GM-CSF binding and signalling. Deletion of the Ig-like domain abolished direct GM-CSF binding and decreased growth signalling in the presence of hbetac. To locate the specific residues in the Ig-like domain of GM-CSFRalpha involved in GM-CSF binding, a structural alignment was made with a related receptor, IL-13Ralpha1 (interleukin-13 receptor alpha1), whose structure and mode of interaction with its ligand has recently been elucidated. Mutagenesis of candidate residues in the predicted region of interaction identified Val51 and Cys60 as having critical roles in binding to the alpha receptor, with Arg54 and Leu55 also being important. High-affinity binding in the presence of hbetac was strongly affected by mutation of Cys60 and was also reduced by mutation of Val51, Arg54 and Leu55. Of the four key residues, growth signalling was most severely affected by mutation of Cys60. The results indicate a previously unrecognized role for the Ig-like domain, and in particular Cys60, of GM-CSFRalpha in the binding of GM-CSF and subsequent activation of cellular signalling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20078425     DOI: 10.1042/BJ20091745

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  5 in total

1.  Two modes of beta-receptor recognition are mediated by distinct epitopes on mouse and human interleukin-3.

Authors:  Shamaruh Mirza; Jinglong Chen; Bin Wen; Cameron L Ewens; Jin Dai; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

2.  STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis.

Authors:  Ping Li; David Harris; Zhiming Liu; Uri Rozovski; Alessandra Ferrajoli; Yongtao Wang; Carlos Bueso-Ramos; Inbal Hazan-Halevy; Srdana Grgurevic; William Wierda; Jan Burger; Susan O'Brien; Stefan Faderl; Michael Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2014-05-16       Impact factor: 5.852

3.  The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities.

Authors:  Urmi Dhagat; Timothy R Hercus; Sophie E Broughton; Tracy L Nero; Karen S Cheung Tung Shing; Emma F Barry; Christy A Thomson; Steve Bryson; Emil F Pai; Barbara J McClure; John W Schrader; Angel F Lopez; Michael W Parker
Journal:  MAbs       Date:  2018-09-12       Impact factor: 5.857

4.  High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

Authors:  Timothy R Hercus; Emma F Barry; Mara Dottore; Barbara J McClure; Andrew I Webb; Angel F Lopez; Ian G Young; James M Murphy
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

5.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.